Keyphrases
Heart Failure
68%
Confidence Interval
42%
Atrial Fibrillation
37%
Patients with Heart Failure
34%
Myocardial Infarction
34%
Hazard Ratio
34%
National Cohort Study
28%
All-cause Mortality
25%
ST-elevation Myocardial Infarction (STEMI)
24%
Out-of-hospital Cardiac Arrest
23%
Acute Myocardial Infarction
22%
Cardiovascular Mortality
21%
Heart Failure with Preserved Ejection Fraction (HFpEF)
20%
Dapagliflozin
19%
Denmark
18%
Reduced Ejection Fraction
16%
Infective Endocarditis
14%
Heart Failure Hospitalization
14%
Comorbidity
14%
Heart Failure Patients
13%
Left Ventricular Ejection Fraction
13%
Diabetes
12%
Nationwide Registry
12%
Adverse Outcomes
11%
Copenhagen
11%
High Risk
11%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
11%
Risk of Death
9%
Type 2 Diabetes Mellitus (T2DM)
9%
Clinical Outcomes
9%
AIMS™
9%
Primary Percutaneous Coronary Intervention
8%
Hospitalization
8%
Cardiovascular Risk
8%
Heart Failure Trials
8%
Mortality Risk
8%
Placebo
8%
Acute Coronary Syndrome
8%
Beta-blockers
8%
Cardiovascular Disease
8%
Percutaneous Coronary Intervention
7%
Left Ventricular Function
7%
Incidence Rate
7%
Odds Ratio
7%
Randomized Controlled Trial
7%
Implantable Defibrillator
7%
Preserved Ejection Fraction
7%
Prognostic Importance
7%
Ischemic Heart Disease
7%
Coronary Artery Disease
7%
Medicine and Dentistry
Heart Failure
70%
Cardiovascular System
29%
Atrial Fibrillation
28%
Hazard Ratio
23%
Myocardial Infarction
22%
Cohort Analysis
21%
Out of Hospital Cardiac Arrest
18%
Ejection Fraction
17%
ST Segment Elevation Myocardial Infarction
17%
Apoplexy
15%
Diabetes
14%
Cardiovascular Disease
12%
Infective Endocarditis
11%
All Cause Mortality
11%
Acute Heart Infarction
9%
Prevalence
9%
Heart Left Ventricle Ejection Fraction
8%
Acute Coronary Syndrome
8%
Dapagliflozin
8%
Maturity Onset Diabetes of the Young
8%
Implantable Automatic Defibrillator
8%
Placebo
7%
Heart Failure with Reduced Ejection Fraction
7%
COVID-19
7%
Percutaneous Coronary Intervention
7%
Disease
7%
Proportional Hazards Model
7%
Coronary Artery Disease
6%
Population
6%
Randomized Controlled Trial
6%
Coronary Angiography
6%
Cardiac Magnetic Resonance Imaging
6%
Primary Percutaneous Coronary Intervention
6%
Electrocardiogram
5%
Systolic Heart Failure
5%
Ischemic Heart Disease
5%
Cardiovascular Risk
5%
Symptom
5%
Drug Therapy
5%
Population Research
5%
Resuscitation
5%
Adverse Outcome
5%
Amino Terminal Sequence
5%
Echocardiography
5%
Patient with Type 2 Diabetes
5%
Brain Natriuretic Peptide
5%
Multidetector Computed Tomography
5%
Revascularization
5%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Heart Infarction
37%
Atrial Fibrillation
27%
Cohort Study
23%
ST Segment Elevation Myocardial Infarction
20%
Dapagliflozin
19%
All Cause Mortality
19%
Acute Heart Infarction
19%
Non Insulin Dependent Diabetes Mellitus
12%
Heart Failure with Reduced Ejection Fraction
12%
Adverse Outcome
11%
Disease
11%
Placebo
11%
Comorbidity
11%
Cardiovascular Disease
9%
Prevalence
9%
Bacterial Endocarditis
9%
Out of Hospital Cardiac Arrest
9%
Brain Natriuretic Peptide
9%
Infarction
8%
Cardiovascular Risk
6%
Dipeptidyl Carboxypeptidase Inhibitor
6%
Systolic Heart Failure
6%
Anticoagulant Agent
6%
Valsartan/Sacubitril
6%
Acute Coronary Syndrome
5%
Diabetes Mellitus
5%
Coronary Artery Disease
5%
Heart Failure with Preserved Ejection Fraction
5%
Ischemic Heart Disease
5%
Thromboembolism
5%
Bleeding
5%
Symptom
5%